During the last forty years we have witnessed impressive advances in the field of antiviral
drug discovery culminating with the introduction of therapies able to stop human …

Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that
specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious …

Background & Aims Little is known about substitutions that mediate resistance of hepatitis C
virus (HCV) to direct-acting antivirals (DAAs), due to the small number of patients with …

Populations of RNA viruses are composed of complex and dynamic mixtures of variant
genomes that are termed mutant spectra or mutant clouds. This applies also to SARS-CoV …

The approval of combination therapies with direct-acting antiviral (DAA) regimens has led to
significant progress in the field of hepatitis C virus (HCV) treatment. Although most patients …

The elimination of hepatitis C virus (HCV) has been made possible through the availability of
new antiviral drugs which may now be administered to all patients with HCV infection, even …

Background & Aims There are limited data on patients with chronic HCV infection in whom
combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus …

A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-
based treatment regimens, often because of drug resistance-associated substitutions (RAS) …

Hepatitis C virus (HCV) core is a highly conserved and multifunctional protein that forms the
viral capsid, making it an attractive target for HCV detection and inhibition. Aptamers are in …

The quasispecies dynamics of viral populations (continuous generation of variant genomes
and competition among them) has as one of its frequent consequences variations in overall …